Medicine and Dentistry
Denosumab
71%
Osteoporosis
36%
Osteolysis
35%
Bone Turnover
33%
Alendronic Acid
28%
Hypercalcaemia
28%
Zoledronic Acid
24%
Cohort Analysis
16%
Parathyroid
14%
Osteoclast Differentiation Factor
14%
Wart Virus
14%
Prostate Cancer
14%
Acid Phosphatase Tartrate Resistant Isoenzyme
14%
Head and Neck Squamous Cell Carcinoma
14%
Liquid Paraffin
14%
Osteoclast
14%
Hip
13%
Dual-Energy X-Ray Absorptiometry
11%
Side Effect
10%
Elderly Patient
10%
Isotopes of Calcium
9%
Glucocorticoid
8%
Calcitriol
8%
Lumbar Spine
7%
Elderly Population
7%
Osteopenia
6%
Granuloma
5%
Hypercalciuria
5%
Kidney Function
5%
Calcium Ion
5%
Parathyroid Hormone
5%
Pharmacology, Toxicology and Pharmaceutical Science
Denosumab
100%
Zoledronic Acid
46%
Romosozumab
42%
Alendronic Acid
30%
Cohort Study
18%
Side Effect
18%
Clinical Trial
17%
Prostate Cancer
14%
Combination Therapy
14%
Abaloparatide
14%
Liquid Paraffin
14%
Bisphosphonic Acid Derivative
14%
Parathyroid hormone[1-34]
14%
Hypercalcaemia
14%
Comorbidity
14%
Polypharmacy
14%
Vitamin D
14%
Sclerostin
7%
Spine Fracture
7%
Osteopenia
6%
Immunology and Microbiology
Denosumab
85%
Osteolysis
50%
Hip
39%
Bone Turnover
36%
Bone Density
17%
Lumbar Spine
16%
Wart Virus
14%
RANKL
14%
Osteoclast
14%
Neck
14%
Squamous Cell
14%
Bone Mass
9%
Carboxy Terminal Sequence
7%
Spine
7%
Prostate
6%
Postmenopause
5%
Femoral Neck
5%
